|
1
|
Li YX, Liu QF, Fang H, Qi SN, Wang H, et
al: Variable clinical presentations of nasal and Waldeyer ring
natural killer/T-cell lymphoma. Clin Cancer Res. 15:2905–2912.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li YX, Wang H, Jin J, Wang WH, Liu QF, et
al: Radiotherapy alone with curative intent in patients with stage
I extranodal nasal-type NK/T-cell lymphoma. Int J Radiat Oncol Biol
Phys. 82:1809–1815. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kohrt H, Lee M and Advani R: Risk
stratification in extranodal natural killer/T-cell lymphoma. Expert
Rev Anticancer Ther. 10:1395–1405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamaguchi M, Tobinai K, Oguchi M, Ishizuka
N, Kobayashi Y, Isobe Y, et al: Phase I/II study of concurrent
chemoradiotherapy for localized nasal natural killer/T-cell
lymphoma: Japan Clinical Oncology Group study JCOG0211. J Clin
Oncol. 27:5594–5600. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF,
et al: First-line combination of gemcitabine, oxaliplatin, and
L-asparaginase (GELOX) followed by involved-field radiation therapy
for patients with stage IE/IIE extranodal natural killer/T-cell
lymphoma. Cancer. 119:348–355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baekelandt M, Lehne G, Tropé CG, Szántó I,
Pfeiffer P, Gustavssson B and Kristensen GB: Phase I/II trial of
the multidrug-resistance modulator valspodar combined with
cisplatin and doxorubicin in refractory ovarian cancer. J Clin
Oncol. 19:2983–2993. 2001.PubMed/NCBI
|
|
7
|
Shiraki N, Hamada A, Ohmura T, Tokunaga J,
Oyama N and Nakano M: Increase in doxorubicin cytotoxicity by
inhibition of P-glycoprotein activity with lomerizine. Biol Pharm
Bull. 24:555–557. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang B, Li XQ, Ma X, Hong X, Lu H and Guo
Y: Immunohistochemical expression and clinical significance of
P-glycoprotein in previously untreated extranodal NK/T-cell
lymphoma, nasal type. Am J Hematol. 83:795–799. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamaguchi M, Kwong YL, Kim WS, Maeda Y,
Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, et al:
Phase II study of SMILE chemotherapy for newly diagnosed stage IV,
relapsed, or refractory extranodal natural killer (NK)/T-cell
lymphoma, nasal type: The NK-Cell Tumor Study Group study. J Clin
Oncol. 29:4410–4416. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Martin JK, Sun W, Moraga-A D, Schuster SM
and Wylie DE: An investigation into the mechanism of L-asparaginase
resistance in L5178Y murine leukemia cells. Amino Acids. 5:51–69.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tse E and Kwong YL: How I treat NK/T-cell
lymphomas. Blood. 121:4997–5005. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van den Berg H: Asparaginase revisited.
Leuk Lymphoma. 52:168–178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jaccard A, Gachard N, Marin B, Rogez S,
Audrain M, et al: Efficacy of L-asparaginase with methotrexate and
dexamethasone (AspaMetDex regimen) in patients with refractory or
relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood.
117:1834–1839. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chie WC, Yang CH, Hsu C and Yang PC:
Quality of life of lung cancer patients: Validation of the Taiwan
Chinese version of the EORTC QLQ-C30 and QLQ-LC13. Qual Life Res.
13:257–262. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang L, Xia ZJ, Huang HQ, et al:
Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)
in the treatment of stage IE/IIE extranodal natural killer/T cell
lymphoma, nasal type: 13-year follow-up in 135 patients. Int J
Hematol. 96:617–623. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamaguchi M, Tobinai K, Oguchi M, Ishizuka
N, Kobayashi Y, Isobe Y, et al: Concurrent chemoradiotherapy for
localized nasal natural killer/T-cell lymphoma: An updated analysis
of the Japan clinical oncology group study JCOG0211. J Clin Oncol.
30:4044–4046. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rosenquist R, Davi F and Ghia P: The
microenvironment in lymphomas - dissecting the complex crosstalk
between tumor cells and ‘by-stander’ cells. Semin Cancer Biol.
24:1–2. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin ZX, Bai B, Cai QC, et al: High numbers
of tumor-associated macrophages correlate with poor prognosis in
patients with mature T- and natural killer cell lymphomas. Med
Oncol. 29:3522–3528. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim HS, Kim KH, Kim KH, Chang MH, Ji SH,
et al: Whole blood Epstein-Barr virus DNA load as a diagnostic and
prognostic surrogate: Extranodal natural killer/T-cell lymphoma.
Leuk Lymphoma. 50:757–763. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Suzuki R, Yamaguchi M, Izutsu K, Yamamoto
G, Takada K, Harabuchi Y, et al: Prospective measurement of
Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear
cells of extranodal NK/T-cell lymphoma, nasal type. Blood.
118:6018–6022. 2011. View Article : Google Scholar : PubMed/NCBI
|
